Latest Hotspot

Mission Therapeutics Launches Key Study on MTX325 for Parkinson’s Disease Progression

27 March 2024
3 min read

Mission Therapeutics, an enterprise focused on clinical-phase biotechnological advancements, has initiated a Phase I human trial for MTX325. This inaugural study explores the therapeutic effects of this novel intervention aimed at mitophagy manipulation, with the goal of altering the progression of Parkinson’s Disease.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Globally, approximately 10 million individuals are battling Parkinson’s Disease, with nearly a million cases in the United States and about 1.2 million across Europe. These figures are likely to rise due to demographic shifts towards older populations.

At Mission Therapeutics, the initial group of healthy participants has been successfully administered doses as part of a segmented, flexible Phase I trial to determine the safety, tolerability, pharmacokinetic profiles, and the extent of MTX325's penetration into the brain. Plans for 2024 include to conduct dosing escalation studies in both single and multiple instances, as well as trials involving senior volunteers, followed by a special focus on Parkinson’s Disease sufferers in 2025.

Dr. Paul Thompson, PhD, the Chief Scientific Officer at Mission Therapeutics, commented: “Initiating this first-in-human trial marks a critical advancement for our company. We are eager to evaluate the efficacy of MTX325 as a drug that may alter the progression of Parkinson’s Disease. Despite current therapeutic options mitigating certain symptoms like tremors, movement rigidity, and mental difficulties, the progressive degeneration of neurons, which is fundamental to the severity of the disease, remains unaddressed.”

The commencement of this clinical study succeeded the release of a pivotal scientific article in the journal Nature Communications last December, authored by experts from Cambridge University, Harvard University, and Mission Therapeutics. The publication presented data from preclinical mouse model studies that offered considerable evidence supporting the hypothesis that MTX325 has the potential to alter Parkinson’s Disease progression by honing in on USP30.

USP30, a deubiquitylating enzyme, has been shown to obstruct mitophagy, a cellular clearance method for removing impaired mitochondria. An expanding compendium of scientific research has connected the accumulation of malfunctioning mitochondria within cells to various illnesses, which includes Parkinson’s Disease, Kidney Disease, Heart Failure, idiopathic pulmonary fibrosis, and Duchenne’s Muscular Dystrophy.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

According to the data provided by the Synapse Database, As of March 25, 2024, there are 2 investigational drugs for the USP30 target, including 4 indications, 1 R&D institutions involved, and as many as 454 patents.

MTX-325 targets USP30 and is primarily intended for the treatment of Parkinson's Disease. The drug is currently in Phase 1 of clinical development and has potential therapeutic applications in Nervous System Diseases and Endocrinology and Metabolic Disease. Further research and clinical trials will be necessary to determine its efficacy and safety.

图形用户界面, 文本, 应用程序

描述已自动生成

Sumitomo Pharma Renews Collaborative Development Agreement with Otsuka Pharmaceutical for Multiple Psychiatric Disorder Treatments
Hot Spotlight
8 min read
Sumitomo Pharma Renews Collaborative Development Agreement with Otsuka Pharmaceutical for Multiple Psychiatric Disorder Treatments
27 March 2024
Sumitomo Dainippon Pharma and its U.S. subsidiary SMPA announced an updated agreement on March 15th with Otsuka Pharmaceutical for the joint development of four psychiatric and neurological compounds, including ulotaront and others, amending their original September 30, 2021, partnership.
Read →
Italfarmaco's Duvyzat™ Approved by FDA for Duchenne Muscular Dystrophy
Latest Hotspot
3 min read
Italfarmaco's Duvyzat™ Approved by FDA for Duchenne Muscular Dystrophy
27 March 2024
FDA Clears Italfarmaco's Duvyzat™ (givinostat) for Treatment of Duchenne Muscular Dystrophy.
Read →
Maximize Your Synapse Use: Your Guide to Searching Indomethacin
Drug Insights
2 min read
Maximize Your Synapse Use: Your Guide to Searching Indomethacin
27 March 2024
Indomethacin is a small NSAID that blocks the COX enzyme to reduce inflammation and pain.
Read →
FDA Approves Vertex's Clinical Trials for ADPKD Drug VX-407
Latest Hotspot
3 min read
FDA Approves Vertex's Clinical Trials for ADPKD Drug VX-407
26 March 2024
Vertex has received authorization from the FDA to proceed with clinical trials for VX-407, a new drug candidate targeting the management of ADPKD.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.